Ming‐Sound Tsao, Lynette M. Sholl, Michelle Shiller, Peter B. Illei, Ignacio I. Wistuba, Mary Beth Beasley, Kurt A. Schalper, Archana R. Simmons, Peter Ansell, Sue Beruti, Mari Mino–Kenudson
MET protein (also known as c-Met protein) overexpression (OE) is an emerging clinically relevant biomarker that is targetable with antibody-drug conjugates. c-Met protein's prevalence varies, depending on the different OE thresholds, antibodies, and detection methodologies used. Unlike MET genomic aberrations, MET protein OE is a protein biomarker requiring immunohistochemistry (IHC)-based testing. Herein, we summarize the current evidence on MET protein OE, including prognostic value, heterogeneity, and stability. We also provide key considerations for enabling optimal real-world testing of this IHC-based biomarker.